| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 17,151 | 28,301 | 29,382 | 41,673 |
| Research and development, net | 23,265 | 29,579 | 34,893 | 39,134 |
| General and administrative | 10,398 | 10,338 | 11,315 | 13,276 |
| Total operating expenses | 33,663 | 39,917 | 46,208 | 52,410 |
| Loss from operations | -16,512 | -11,616 | -16,826 | -10,737 |
| Loss from foreign currency | -170 | -127 | -21 | -201 |
| Finance income, net | 3,234 | 2,567 | 2,771 | 3,818 |
| Net loss before income taxes | -13,448 | -9,176 | -14,076 | -7,120 |
| Provision (benefit) for income taxes | - | 4 | - | -217 |
| Net loss | -13,448 | -9,180 | -14,076 | -6,903 |
| Comprehensive loss | -13,448 | -9,180 | -14,076 | -6,903 |
| Basic | -0.49 | -0.34 | -0.52 | -0.26 |
| Basic | 27,188,000 | 27,129,000 | 27,107,000 | 27,062,000 |
| Diluted | -0.49 | -0.34 | -0.52 | -0.26 |
| Diluted | 27,188,000 | 27,129,000 | 27,107,000 | 27,062,000 |
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)